We Are Better Together
At VBI, we believe that it takes the power of many great minds and organizations to solve the toughest challenges.
We value our partnerships with teams that share our philosophy and vision, and continue to seek meaningful collaborations across industry, government, and advocacy and patient groups.
Action Hepatitis Canada (AHC)
VBI supports Action Hepatitis Canada (AHC), a national coalition of organizations responding to viral hepatitis, in their work to engage government, policy makers, and civil society to promote viral hepatitis prevention, create public health awareness, build health-professional capacity, and support community-based groups and initiatives.
Adult Vaccine Access Coalition
VBI is a corporate member of the Adult Vaccine Access Coalition (AVAC), which was formed to advocate for federal policies that improve access to and increase utilization of vaccines among adults. Near universal access to immunizations for children has been one of the greatest public health accomplishments of the 20th Century, and VBI is working with AVAC to achieve the same level of success among adults.
Association of Immunization Managers
VBI is a corporate alliance member of the Association of Immunization Managers (AIM), a nonprofit organization dedicated to establishing a nation free of vaccine-preventable disease. AIM members are the leaders of state, local, and territorial immunization programs directing the public health efforts designed to keep children and adults vaccinated and protected against disease.
Brii Biosciences (Brii Bio)
VBI and Brii Bio have a license and collaboration agreement for the development of VBI-2601 (BRII-179) as part of a potential functional cure for chronic hepatitis B infection.
Government of Canada
Through their Strategic Innovation Fund, the Government of Canada awarded VBI up to a CAD $56 million contribution to support the development of the Company’s prophylactic coronavirus vaccine candidates, VBI-2901 and VBI-2902, through Phase 2 clinical studies.
Coalition for Epidemic Preparedness Innovations (CEPI)
As part of their collaboration, CEPI will provide VBI up to $33M of funding to support development of VBI’s eVLP vaccine candidates against COVID-19 variants of concern, including B.1.351, the variant first identified in South Africa.
VBI and GSK have a collaboration to clinically evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic candidate, with GSK’s proprietary AS01 adjuvant system in patients with recurrent glioblastoma (GBM).
Hepatitis B Foundation
The Hepatitis B Foundation (HBF) is a national nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. VBI supports HBF’s work on promoting disease awareness and immunization initiatives.
VBI is a corporate member of Immunize.org (formerly the Immunization Action Coalition – IAC) and supports its work to increase immunization rates and prevent disease by creating and distributing educational materials for healthcare professionals and the public that enhance the delivery of safe and effective immunization services.
National Foundation for Infectious Diseases (NFID)
VBI is a Silver Level Strategic Partner of the National Foundation for Infectious Diseases (NFID), and supports their important work to educate the public and healthcare professionals about the burden, causes, prevention, diagnosis, and treatment of infectious diseases across the lifespan.
National Research Council of Canada (NRC)
VBI and the NRC have a collaboration to develop a COVID-19 vaccine candidate and a pan-coronavirus vaccine candidate, targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS). This is the latest collaboration in a series of collaborations with the NRC, which have included research and development on a number of preclinical programs.
Resilience Biotechnologies, Inc. (Resilience)
(previously Therapure Biopharma Inc.)
VBI and Resilience have an agreement for the development and manufacturing services in preparation for production of its coronavirus vaccine candidates. The collaboration is expected to support clinical studies through Phase 2 clinical development.
We are always seeking meaningful and innovative partnerships to prevent or treat disease.
If you are interested in learning more about a potential collaboration with us, please contact us at: